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ABSTRACT
Introduction: Accurate identification of pathogens,
rather than colonising bacteria, is a prerequisite for
targeted antibiotic therapy to ensure optimal patient
outcome in wounds, such as diabetic foot ulcers. Wound
swabs are the easiest and most commonly used sampling
technique but most published guidelines recommend
instead removal of a tissue sample from the wound bed,
which is a more complex process. The aim of this study
was to assess the concordance between culture results
from wound swabs and tissue samples in patients with
suspected diabetic foot infection.
Methods and analysis: Patients with a diabetic foot
ulcer that is thought to be infected are being recruited
from 25 sites across England in a cross-sectional study.
The coprimary endpoints for the study are agreement
between the two sampling techniques for three
microbiological parameters: reported presence of likely
isolates identified by the UK Health Protection Agency;
resistance of isolates to usual antibiotic agents; and, the
number of isolates reported per specimen. Secondary
endpoints include appropriateness of the empiric
antibiotic therapy prescribed and adverse events.
Enrolling 400 patients will provide 80% power to detect a
difference of 3% in the reported presence of an organism,
assuming organism prevalence of 10%, discordance of
5% and a two-sided test at the 5% level of significance.
Assumed overall prevalence is based on relatively
uncommon organisms such as Pseudomonas. We will
define acceptable agreement as κ>0.6.
Ethics and dissemination: Concordance in diabetic
foot ulcer infection (CODIFI) will produce robust data to
evaluate the two most commonly used sampling
techniques employed for patients with a diabetic foot
infection. This will help determine whether or not it is
important that clinicians take tissue samples rather than
swabs in infected ulcers. This study has been approved
by the Sheffield NRES Committee (Ref: 11/YH/0078) and
all sites have obtained local approvals prior starting
recruitment.
Study registration: NRES Ref: 11/YH/0078, UKCRN ID:
10440, ISRCTN: 52608451
INTRODUCTION
The global prevalence of diabetes is esti-
mated to be 3% and predicted to double by
2030, largely due to the obesity epidemic.1
Among the complications of diabetes, those
involving peripheral nerves and arteries
predispose to foot complications. These
include alterations in foot architecture and
mechanics that lead to increased pressure on
the plantar surfaces.2 3 These changes, com-
bined with peripheral sensory and auto-
nomic neuropathy, increase susceptibility to
trauma and dry skin ﬁssures.4 5 The
ARTICLE SUMMARY
Article focus
▪ Accurate identification of pathogens, rather than
colonising bacteria, is a prerequisite for targeted
antibiotic therapy to ensure optimal patient
outcome in diabetic foot ulcers.
▪ There is a lack of robust evidence to advise clini-
cians on the best technique to identify pathogens
in diabetic foot ulcers.
▪ The aim of this study was to assess the concord-
ance between culture results from wound swabs
and tissue samples in patients with infected dia-
betic foot ulcers.
Key messages
▪ This protocol details the design of the first pro-
spective multicentre study to examine agreement
between different wound sampling techniques in
patients with diabetic foot ulcers.
▪ Results from this study will be directly relevant
to all clinicians treating patients with diabetic
foot ulcers.
Strengths and limitations of this study
▪ The sample size of 400 patients will provide
80% power for detecting a difference of 3% in
the reported presence of organisms.
▪ Recruiting patients from 25 sites across England
increases the external validity of results.
▪ The subset of samples processed using molecu-
lar (PCR) techniques will allow the largest com-
parison of this technology with the conventional
plating techniques in diabetic foot ulcers.
However, further work will still be required to
fully evaluate the role of PCR techniques in the
care of diabetic foot ulcers.
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additional presence of peripheral vascular disease
impairs wound healing. Thus, it is not surprising that
foot ulceration occurs in 15–25% of diabetic patients
during the course of their disease.6 7
Diabetic foot ulcers can take many weeks or often
months to heal and are known to have a negative impact
on patients’ functional ability, quality of life, as well as a
wider societal impact in terms of reduced work product-
ivity, health costs and ﬁnancial loss.8–11 The combination
of immunological perturbations caused by diabetes and
an open wound frequently results in clinically apparent
infection. At presentation about half of recent onset
diabetic foot ulcers are clinically infected.12 Diabetic
foot infection is thought to be the most common cause
of diabetes-related hospital admissions and precedes
approximately 80% of non-traumatic lower-limb
amputations.6 13 14
All chronic wounds have bacteria on their surface,
which mostly originate from the normal skin ﬂora, some-
times supplemented by opportunistic colonising bac-
teria. Thus, the presence of bacteria within a wound is
not sufﬁcient to diagnose infection. Infection is instead
a clinical diagnosis based on signs and symptoms such as
fever, pus, pain or tenderness, erythema, warmth and
induration.15 These ﬁndings suggest a shift in balance in
favour of the bacteria within the ulcer over the host’s
defences, with consequent destruction of host tissue.
When infection is diagnosed, antibiotic therapy is
initiated which is usually empirically selected, based on
the clinician’s understanding of the likely causative
organisms. To modify the empiric treatment, if needed,
clinicians seek to identify the infective organisms within
the wound and their antibiotic susceptibilities through
microbiological evaluation.16 This may contribute to the
clinical diagnosis of infection (by the isolation of
virulent organisms likely to be pathogens, or a heavy
bacterial load of less virulent organisms). Crucially, it
also allows targeted treatment with the most appropriate
antibiotic agent for speciﬁc organisms, thus reducing
the overuse of broad spectrum antimicrobials, which is
associated with increasing antibiotic resistance.15–17
Currently, culture and sensitivity results typically take
several days before they are reported to clinicians, during
which time the patient is often treated with broad spec-
trum antibiotic(s) so as to cover all potential pathogens.
Furthermore, it is not clear as to whether clinically rele-
vant changes in the wound ﬂora occur between initial
sample and test results being available at reassessment.
Quicker techniques for microbiological analyses, such as
those based on DNA ﬁngerprinting techniques or the
PCR assay, have been shown to be effective in rapidly
detecting causative organisms and may help reduce this
delay.18 In theory, this might lead to earlier tailoring of
antimicrobial therapy to infecting organism(s).
The accuracy of the culture information is crucially
dependent on an appropriate specimen, that is, one
from the infected site that is not contaminated by sur-
rounding normal ﬂora, being sent to the laboratory.
The specimen must also be quickly transported and
inoculated on plates to avoid losing pathogens or allow-
ing contaminants to proliferate. Failing to identify a true
pathogen (poor test sensitivity) or identifying a colon-
iser as a pathogen (poor speciﬁcity) can each lead to
incorrect antibiotic therapy and worse treatment out-
comes. Thus, it is important that clinicians use a tech-
nique to obtain specimens that will give a valid account
of the bacteria present and their number and sensitivity
to antibiotics.
Need for a study
Swabs for taking a culture are almost universally available
in healthcare settings and are quick and easy to use. But,
they may be susceptible to collecting contaminants and
to failing to grow some pathogens. In order to send a spe-
cimen from which pathogens are likely to grow, most pub-
lished expert guidelines recommend obtaining a tissue
specimen rather than a swab.19 20 Many cite the study by
Pellizzer et al,21 which reported on 29 diabetic patients
who were suspected of severe infection and were neither
recently treated with antibiotics, nor hospitalised. The
analysis of the study did not report agreement between
swab and tissue sample, however, simply the number of
bacterial colonies in each sample. Their conclusion that
tissue samples are better than swabs can be traced to a
comparison of the numbers of isolates in 21 people
remaining in the study at 30 day. Furthermore, this
selected population does not reﬂect many of the foot
ulcer patients seen in foot clinics, who have often been
treated with antibiotics. More recently, Slater et al22
reported the results from swabs and a deeper tissue
sample (obtained via needle aspiration), but their study
only contained 30 diabetic patients with foot ulcers (in a
total sample of 60; other patients had deep abscesses,
etc). They found that in 37 patients (62% of samples),
there was a similar proﬁle of organisms isolated from the
swab and the deep tissue sample. In 12 patients (20% of
samples), the swab identiﬁed more organisms and in 11
patients (18% of samples) the deeper tissue sample iden-
tiﬁed more organisms. These data were not stratiﬁed by
the presence or absence of ulcer, or ulcer type (neuro-
pathic/ischaemic) and it is not clear if the results were
heterogeneous across tissue damage types or applied to
tissue samples.
A systematic review of the diagnosis and management
of infection in diabetic foot ulcers23 found only one
study that evaluated sample acquisition and reported
agreement in sufﬁcient detail to allow full analysis. This
study, by Bill et al,24 included patients with a variety of
wounds: 18 pressure ulcers, 10 diabetic foot ulcers, 5
venous leg ulcers and 5 arterial ulcers. A punch biopsy
was taken from the centre of the wound and compared
with a wound swab with quantitative analysis. Swabs were
not taken from wounds with a bacterial load of less than
105 colony-forming units bacteria per gram of tissue.
The presence of infection was deﬁned by bacterial load
(one million bacteria per gram of tissue). The sensitivity
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for wound swabbing was reported as 79%, meaning that
the swab failed to detect approximately one in ﬁve
wound infections as deﬁned by culture of tissue
obtained by punch biopsy. The derived likelihood ratios
suggested that the wound swab was not a useful method
of identifying infection in chronic wounds.
Interpretation of study ﬁndings is impeded by small size
and heterogeneity in the ulcer population.
It may be that these data are not directly transferable to
a clinical diabetic population with a diagnosis of foot
ulcer infection (ie, clinical indication for a swab). In add-
ition, there were potential sources of bias, such as the
lack of a description of blind test veriﬁcation and clarity
as to whether the same clinical data were available when
test results were interpreted as would be available when
the test is used in practice. Furthermore, the research
question addressed in this proposed study is not about
‘diagnosis of infection’ (ie, would both tissue sample and
swab agree for an arbitrary bacterial load of >105 colony-
forming units bacteria per gram of tissue for tissue biopsy
and >105 colony-forming units bacteria/cm2 for swab cul-
tures) as the diagnosis of infection (present or absent) is
a clinical decision. People with a bacterial load of <105
colony-forming units bacteria per gram of tissue did not
have a wound swab, and it is not clear, therefore, if the
swab provides additional information, as suggested by
Pellizzer et al.21 Thus, the study by Bill et al24 cannot con-
clude that swabs of clinically infected diabetic ulcers do
not provide similar information as tissue samples
obtained through tissue samples.
Objectives
Primary objective
The primary objective of this study was to evaluate con-
cordance (agreement) between culture results from
wound swabs and tissue samples from the same patient.
The coprimary endpoints for the study are agreement
between the two techniques for three microbiological
parameters.
▸ Reported presence of isolates likely to be pathogens,
as identiﬁed by the UK Health Protection Agency
(HPA).
▸ The presence of resistance to antibiotics to which the
isolates are usually sensitive among likely isolates as
reported by standard techniques.
▸ The number of bacterial isolates reported per speci-
men (swab/tissue sample).
Secondary objectives
Secondary objectives are to
▸ Compare the proportions of patients for whom
empirical antibiotic therapy was ‘appropriate’, based
on culture and sensitivity results of swab or tissue
samples, assessed by a blinded clinical panel review
(with record of antimicrobial therapy prescribed).
▸ Compare the number of isolates, reported in both
the swab and tissue samples by conventional plating
and culture, against molecular techniques (ie, PCR)
that identify the nucleic acids of bacteria in the
wound.
▸ Compare rates of adverse effects with the two
techniques.
▸ Compare costs of sampling with the two techniques.
METHODS AND ANALYSIS
Study design
This is a multicentre, cross-sectional study involving 400
patients with diabetes presenting with a foot ulcer sus-
pected of being infected who are thought by their clini-
cians to require antibiotic therapy (see ﬁgure 1).
Consenting patients will have both a swab and tissue
sample taken from their foot ulcer for conventional
plating and culture. In addition, 20 patients will be
included in a substudy in which a second-swab sample
and half of the tissue sample will be processed using
molecular (PCR) techniques for comparison with the
conventional plating techniques.
Eligibility
All patients at least 18 years of age with a diabetic foot
ulcer that the clinician suspects is infected, either
acutely or as a chronic infection, will be screened for
enrolment and must meet the eligibility criteria below.
A diabetic foot ulcer will be considered to be any open
wound on the foot (below the malleoli/ankle) in a
patient with a diagnosis of diabetes mellitus. Each par-
ticipant will undergo an eligibility screen prior to entry
and an anonymised log will capture patient demograph-
ics along with reasons for not entering the study.
Inclusion criteria
▸ The patient has a diagnosis of diabetes (type 1 or
type 2).
▸ The patient is at least 18 years of age at the time of
signing the consent form.
▸ The patient has a suspected ulcer infection with or
without bone infection, based on clinical signs and
symptoms using Infectious Diseases Society of America/
International Working Group on the Diabetic Foot cri-
teria and the judgement of the investigator.
▸ The clinical plan is to treat the patient with antibio-
tics for their infected ulcer.
Exclusion criteria
▸ The clinician deems it inappropriate to take a tissue
sample or a swab sample for any reason.
▸ The patient has previously been recruited to the study.
Recruitment and registration
Centres will be required to have obtained local ethical
and management approvals and undertake a site initi-
ation meeting with the Clinical Coordinator prior to the
start of recruitment into the study.
Both inpatients and outpatients will be recruited from
multidisciplinary primary and secondary care-based foot
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ulcer/diabetic clinics and hospital wards. Potential
patients will be provided with a patient information
leaﬂet outlining all aspects of the study, given the
chance to read it and ask any questions they may have
about the study. Written informed consent will be docu-
mented by the patient and member of the local team.
Informed written consent will be obtained from all
patients prior to entering the study. Patients will be regis-
tered via a 24 h automated telephone registration system
that will automatically send conﬁrmation of successful
registration through to the site.
Assessments
Sample acquisition
Clinicians at all centres will be trained to collect samples
using the HPA standards25 26 as a minimum require-
ment. In the ﬁrst instance training will be delivered
during the site initiation visit but staff will also be able to
access an e-learning package containing a video at any
time throughout the study. It is not anticipated that this
will substantially alter current swabbing practice as this is
a routine procedure with established patterns of practice
from the HPA.
Figure 1 Study flow diagram.
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After wound cleansing (using sterile saline and gauze)
and debridement (removal of necrotic tissue, foreign
material, callus, undermining of the wound edge), a
physician, nurse or podiatrist will obtain specimens for
aerobic and anaerobic cultures by
▸ First, using a cotton-tipped swab rubbed over the
wound surface to sample superﬁcial wound ﬂuid and
tissue debris. The swab will be pressed with sufﬁcient
pressure on the wound bed to capture expressed
wound ﬂuid, and will be positioned deep in the ulcer
to collect from likely infected areas. For the substudy
in 20 patients of culturing versus molecular techni-
ques, a wound swab will be collected for conventional
techniques and another for molecular analysis.
▸ Immediately after the cotton swab has been collected,
a tissue sample will be removed from the same area
of the ulcer bed. This procedure will be done using
sterile equipment (forceps, scalpel and scissors) and
aseptic technique. It will involve the removal of a
small piece of wound tissue at the base of the wound
by scraping or scooping using a dermal curette or
sterile scalpel blade.
Training of swab and sampling techniques
Clinicians in the participating sites will participate in a
study information session to update their technique for
acquiring wound samples. Clinicians will also view an
e-learning package that will be developed and issued to
all sites, detailing study procedures. This will include
video footage of correct methods of obtaining both
types of samples.
Sample transport
Both samples will be placed in transport medium suit-
able for sustaining both aerobic and anaerobic organ-
isms and promptly delivered to the local medical
microbiology laboratory, in accordance with standard
practice. A national standard method will be used for
collecting and processing samples.25 26 Both samples will
be processed in the same laboratory.
Sample transport for PCR substudy
For the 20 patients included in the substudy, one swab
sample and half of the tissue sample will be sent for
molecular analysis, via ﬁrst class post at ambient tem-
perature to a specialist laboratory. Upon receipt, samples
will be stored at –70°C and batches will be defrosted
before being processed.
Clinical assessments
In addition to patient demographics, clinicians will
obtain a medical history including information on the
patients’ diabetes. A detailed foot health history will
capture information regarding foot ulcers, including
current or proposed antibiotic treatment and dressings.
Foot wounds will be categorised and scored by both the
PEDIS27 and Wagner28 ulcer classiﬁcation systems, along
with the Clinical Signs and Symptoms Classiﬁcation for
Infection29 to record details of the index ulcer.
A panel will judge the appropriateness of empirical
antibiotic therapy against results of both swab and tissue
sample ﬁndings. The panel will be blind to the source
of sample (tissue sample or swab) and to eliminate bias
samples will be unpaired and mixed up for judging pur-
poses. Panel members will be asked to comment on the
appropriateness of antibiotic selections.
Sample size
The sample size is based on the outcome reported ‘pres-
ence or absence of isolate’ for the whole sample overall.
To be conﬁdent that swabs adequately sample wound
ﬂora we will assume that the chance corrected agree-
ment between swabs and tissue samples needs to be at
least ‘good’: usually deﬁned as a κ>0.6.30
A sample size of 399 patients will provide 80% power
for detecting a difference of 3% in the reported pres-
ence of any given organism, assuming an overall preva-
lence for the organism of 10%, a discordance between
the swab and tissue samples of 5%, and a two-sided test
at the 5% level of signiﬁcance. This amount of agree-
ment would provide a κ of ∼0.7. This calculation is
based on less prevalent organisms, such as Pseudomonas
(present in 10% of samples in ref. 21). Based on these
analyses we plan to recruit a total of 400 patients.
The κ alone does not convey the distribution of dis-
agreement between swabs and tissue samples and that
good overall agreement, with balanced disagreement
around the central axis of a table of distributions, would
be clinically important if tests were to be regarded as
interchangeable. Thus, the total sample size has been
based on good agreement between the sample types and
reasonably balanced discordance (ie, a small difference
due to similar proportions of isolates missed by both
swab and tissue sample culture), for clinically important
and less prevalent organisms.
The substudy (culture vs molecular techniques) will
collect samples from 20 patients to allow an evaluation
of the level of agreement and inform a powered, deﬁni-
tive study.
STATISTICAL ANALYSIS
All tests of statistical signiﬁcance will be two sided with
p values and 95% CIs provided, as appropriate. The
results will be reported in line with the STARD
guidelines.31
Patient populations
All patients registered will be included in the full ana-
lysis set. This analysis population will consist of all
patients registered to take part in the study, regardless of
their adherence to the study protocol or any subsequent
discovery of ineligibility. The full analysis set will be used
for summarising the patient baseline characteristics.
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The evaluable population will consist of all patients
with both evaluable swab and tissue samples. Patients for
whom either the swab or tissue samples were not suc-
cessfully collected or were lost, or for whom the sample
results were lost will not be included in this patient
population. The evaluable population will be used for
the summaries and analyses of all endpoints.
A per-protocol population will be considered if there
are a considerable number of protocol violations. The
per-protocol population will consist of all registered
patients who were not deﬁned protocol violators, which
includes eligibility violators and protocol deviators. The
per-protocol population will be used for the summaries
and analyses of all endpoints.
The safety population will consist of the same patients
in the full analysis set, and will be used for summarising
adverse events (AEs).
Primary endpoint analysis
Reported presence of isolates
For each isolate reported, a cross-tabulation on the semi-
quantitative extent of growth (none, + to +++) will be
generated for swab versus tissue samples, by type of dia-
betic foot ulcer (neuropathic, ischaemic) and overall
and weighted κ will be reported for all tables. Categories
+ to +++ will be combined to record any reported pres-
ence of the isolate.
The corresponding 2×2 table will be created and several
statistics will be reported: prevalence and bias-adjusted κ,
unadjusted κ and overall percentage agreement.
McNemar’s test will be used to test for a difference
between swab and tissue sampling techniques in the pro-
portion of samples with the reported isolate present, to
further investigate the pattern of disagreement.
Summary of isolates reported
An overall summary of isolates reported will be gener-
ated.22 Each pair of results (swab and tissue sample) will
be coded as follows: swab and tissue sample report all
the same isolates; swab reports same isolates as tissue
sample plus extra isolates; tissue sample reports same
isolates as swab plus extra isolates; tissue sample and
swab report different isolates (with or without overlap in
some isolates found).
Multinomial logistic regression will model the propor-
tions in each category on type of ulcer (predominantly
neuropathic or ischaemic), grade of ulcer, previous anti-
biotic therapy, antimicrobial dressing, wound duration
and centre, to determine whether agreement is inﬂu-
enced by any of the speciﬁed covariates. The reference
category will be same isolates reported by both tests; esti-
mates of ORs for each covariate will be presented along
with 95% CIs.
Reported presence of antimicrobial resistance
among likely isolates
Methicillin-resistant Staphylococcus aureus, methicillin-
resistant coagulase-negative staphylococci and
vancomycin-resistant Enterococcus species are the three
antimicrobial-resistant isolates of most interest. For each
of these resistant isolates, 2×2 tables will be created (pres-
ence or absence of resistant isolates) and the following
statistics will be reported: prevalence and bias adjusted κ,
unadjusted κ and overall percentage agreement.
McNemar’s test will be used to test for a difference
between swab and tissue sampling techniques in the pro-
portion of samples in which the speciﬁed resistant
isolate is reported.
For each resistant isolate the following codes will be
created: resistant isolate reported by swab but not tissue
sample, resistant isolate reported by tissue sample but
not swab, swab and tissue sample results agree.
Multinomial regression modelling will model these cat-
egories on type of ulcer (predominantly neuropathic or
ischaemic), grade of ulcer, current antibiotic therapy,
antimicrobial dressing, wound duration and centre to
determine whether agreement is inﬂuenced by any of
the speciﬁed covariates.
Number of isolates reported
Summaries (including cross-tabulations) on the number
of isolates reported per specimen will be generated for
swab versus tissue samples. Samples will be further
coded as follows: tissue sample had two or more extra
isolates reported, tissue sample had one extra isolate
reported, tissue sample and swab had the same number
of isolates reported, swab had one extra isolates reported
or swab had two more extra isolates reported.
Ordinal logistic regression will model the number of
isolates reported per specimen on type of ulcer (ie, pre-
dominantly neuropathic or ischaemic), grade of ulcer,
previous antibiotic therapy, antimicrobial dressing,
wound duration and centre, to determine whether
agreement is inﬂuenced by any of the speciﬁed covari-
ates. The reference category will be the same number of
isolates reported by both tests; estimates of ORs for each
covariate will be presented along with 95% CIs.
Secondary endpoint analysis
Appropriateness of empirical antibiotic therapy
Summaries (including cross-tabulations) will be gener-
ated for the codings: no change to therapy required,
possible change of therapy following the review of clin-
ical course of the patient, deﬁnite change of therapy
required. The ﬁrst two categories will be combined and
the resultant 2×2 table analysed using McNemar’s test to
determine if one test identiﬁes signiﬁcantly more
patients requiring a deﬁnite change in treatment.
Sample pairs will be further coded: results from the
swab but not the tissue sample indicates change in
therapy, results from the tissue sample but not the swab
indicates a change in therapy, swab and tissue sample in
agreement on change in therapy. Multinomial regression
modelling will model these categories on type of ulcer
(predominantly neuropathic or ischaemic), grade of
ulcer, previous antibiotic therapy, antimicrobial dressing,
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wound duration and centre to determine whether agree-
ment is inﬂuenced by any of the speciﬁed covariates.
Number and presence of isolates reported using molecular
or culture techniques
Summaries (including cross-tabulations) on the number
of isolates per specimen reported will be generated.
An overall summary of isolates reported using culture
and molecular techniques will be generated for both
the swab and tissue samples. Each pair of results (from
molecular and culture techniques) will be coded as
follows: molecular and culture report the same isolates;
molecular reports same isolates as culture plus extra iso-
lates; culture reports same isolates as molecular plus
extra isolates; the culture and molecular report different
isolates (with or without overlap in isolates found).
Adverse events
Safety analyses will summarise all AEs, serious AEs and
related unexpected serious AEs. The number of events
and number of patients with events will be summarised.
Sampling costs
Sampling costs will be summarised for each technique.
DISCUSSION
Diabetic foot ulcers are highly prevalent and cause con-
siderable morbidity at both the individual and popula-
tion level.1 8 10 The combination of a chronic wound
and impaired immune defences that may occur in dia-
betes frequently results in infection; although the seque-
lae of these complications range in severity, diabetic foot
infection precedes 80% of non-traumatic lower limb
amputations.6 13 14 Part of the effective treatment of
these infections is providing targeted antibiotic therapy
to improve patient outcome and reduce resistance to
broad spectrum antibiotics.15–17 Despite this, there is a
lack of robust evidence to advise clinicians on the best
technique to identify pathogens in diabetic foot ulcers.
Concordance in diabetic foot ulcer infection
(CODIFI) will generate robust data to evaluate and
compare the two most commonly used wound sampling
techniques. This holds immediate relevance for all clini-
cians working with diabetic foot ulcers.
Study status
CODIFI has received ethical approval from the Shefﬁeld
NRES Committee (Ref: 11/YH/0078) and all sites have
obtained local approvals prior to commencing recruit-
ment. The study is listed on the UKCRN portfolio
(UKCRN ID: 10440) and International Standard
Randomised Controlled Trial Number Register
(ISRCTN: 52608451). Recruitment opened ahead of
schedule in November 2011 and is due to be completed
by the end of March 2013.
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